SB290157 (trifluoroacetate)

SB290157 (trifluoroacetate)

• CAS Number: 1140525-25-2
• UNSPSC Description: SB290157 trifluoroacetate is a potent and selective C3a receptor antagonist with an IC50 of 200 nM.
• Target Antigen: Complement System
• Type: Reference compound
• Related Pathways: Immunology/Inflammation
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/SB290157_trifluoroacetate.html
• Purity: 99.87
• Solubility: DMSO : 100 mg/mL (ultrasonic)|Ethanol : 100 mg/mL (ultrasonic)
• Smiles: N=C(N)NCCC[C@@H](C(O)=O)NC(COCC(C1=CC=CC=C1)C2=CC=CC=C2)=O.OC(C(F)(F)F)=O
• Molecular Weight: 526.51
• References & Citations: [1]Ames RS, et al. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3areceptor that demonstrates antiinflammatory activity in animal models. J Immunol. 2001 May 15;166(10):6341-8.|[2]Hutamekalin P, et al. Effect of the C3a-receptor antagonist SB 290157 on anti-OVA polyclonalantibody-induced arthritis. J Pharmacol Sci. 2010;112(1):56-63.Animals (Basel). 2023 Feb 24.|Brain Behav Immun. 2024 Sep 15:S0889-1591(24)00625-1.|Brain Sci. 2023, 13(2), 262.|Cell Death Dis. 2021 Mar 26;12(4):327.|Free Radic Biol Med. 2023 Jan 4;S0891-5849(23)00003-5.|Front Cell Dev Biol. 02 June 2021.|Immunobiology. 2023 Jan 18;228(2):152337.|Int Immunopharmacol. 2020 Oct;87:106814.|J Am Soc Nephrol. 2022 Jul 1;ASN.2021101384.|J Neuroinflammation. 2021 Feb 15;18(1):43.|J Neuroinflammation. 2024 Sep 16;21(1):227.|J Transl Med. 2023 Dec 11;21(1):904.|Mat Sci Eng C-Mater. 2021, 111932.|Mol Neurobiol. 2024 May 7.|Neurosci Lett. 2023 Feb 6;796:137049.|Prog Neurobiol. 2024 Jun 28:102654.|Research Square Preprint. 2020 Sep.|Toxicol Lett. 2023 Apr 19;S0378-4274(23)00168-6.|Cell Death Dis. 2020 May 15;11(5):377.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported